Oxaliplatin Dose Modification for Colorectal Cancer Triggered by Patient Reported Toxicity: Acceptability and Effect on Chronic Chemotherapy Induced Peripheral Neuropathy

MidCentral Regional Cancer Treatment Services0 个研究点目标入组 30 人开始时间: 2016年11月8日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•1.Male or female patients with histologically proven colorectal adenocarcinoma
•* Histological confirmation of metastatic disease or of the primary lesion where an alternative cause for metastatic disease is considered unlikely
•2.Unresectable metastatic disease with radiological measurable disease according to RECIST v1.1 on computed tomography (CT)
•3.Assessed as suitable for palliative XELOX chemotherapy
•4.No contraindications to capecitabine or oxaliplatin chemotherapy
•5.Able to complete questionnaires and comply with intervention, assessments and follow-up
•6.Written, informed consent

•1.Age < 18 years
•2.Patients with a pre-existing neurological condition including established diabetic peripheral neuropathy
•3.Patients who have previously been treated with neurotoxic chemotherapy agents including platinums, taxanes and vinka-alkaloids
•4.Patients with contra-indications to capecitabine or oxaliplatin

发起方

MidCentral Regional Cancer Treatment Services